Showing 4061-4070 of 5092 results for "".
- FDA Clears Sofwave’s SUPERB Technology for Treating Acne Scarshttps://practicaldermatology.com/news/fda-clears-sofwaves-superb-technology-for-treating-acne-scars/2461969/The U.S. Food and Drug Administration (FDA) has cleared Sofwave’s SUPERB technology for treating acne scars. “Gaining FDA clearance to market SUPERB for the treatment of acne scarring not only paves the way to positively impact patients seeking improved appearances
- Tik Tok Trend Watch: Cyanide as a Potential Acne Cure?https://practicaldermatology.com/news/tik-tok-trend-watch-cyanide-as-a-potential-acne-cure/2461968/Tik Tok is where many trends and DIY challenges get started, and skin care one of the more popular categories for this content. The latest -- a viral video of a woman claiming that she has been 'secretly' feeding her boyfriend seeds containing cyanide (yes, that cyani
- New CEO for SciBasehttps://practicaldermatology.com/news/new-ceo-for-scibase/2461967/Pia Renaudin is SciBase’s new Chief Executive Officer (CEO), effective October 1st, 2023. SciBase's products include Nevisense and Nevisense Go and address melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Ms.
- New App-controlled Device May Help Quickly Identify Infected Woundshttps://practicaldermatology.com/news/new-app-controlled-device-may-help-quickly-identify-infected-wounds/2461959/A new app-controlled device may allow doctors to spot infected wounds faster. The scientists developed a device called the Swift Ray 1 which can be attached to a smartphone and connected to the Swift Skin and Wound software. It can take medical-grade photographs, inf
- Sentient’s Tixel Receives FDA Nod for Treatment of Periorbital Wrinkleshttps://practicaldermatology.com/news/sentients-tixel-receives-fda-nod-for-treatment-of-periorbital-wrinkles/2461945/The device combines heat with the forward motion of a medical-grade titanium tip. The U.S. Food and Drug Administration has approved
- Experts to Develop Human Skin Cell Atlashttps://practicaldermatology.com/news/experts-to-develop-human-skin-cell-atlas/2461944/A grassroots movement to establish a Human Skin Cell Atlas is underway, according to a review in the Journal of Investigative Dermatology. To perform its numerous functions and to maintain pr
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- New Report Highlights Challenges in Evaluating Biosimilarshttps://practicaldermatology.com/news/new-report-highlights-challenges-in-evaluating-biosimilars/2461933/New research provides an overview of gaps and challenges in the value assessment of biosimilars and identifies potential approaches to address them. The report, “
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic